Cargando…

P800: CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Kim, Sojeong, Koh, June-Young, Chung, Haerim, Kim, Yeonhee, Shin, Eui-Cheol, Seok Lee, Jeong, Seok Kim, Jin, Cho, Hyunsoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430724/ http://dx.doi.org/10.1097/01.HS9.0000970104.62297.ea

Ejemplares similares

P851: ANTIBODY TARGETING OF SOLUBLE MHC-CLASS-I-RELATED MOLECULE AUGMENTS NATURAL KILLER CELL FUNCTION BY RESTORING NKG2D IN MULTIPLE MYELOMA
por: Kim, Sojeong, et al.
Publicado: (2023)

Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma
por: Ha, Jihye, et al.
Publicado: (2022)

HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma
por: Park, Hyunsung, et al.
Publicado: (2018)

Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: a single-institution experience
por: Lee, Jung Yeon, et al.
Publicado: (2017)

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2021)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
por: Cho, Hyunsoo, et al.
Publicado: (2021)

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study
por: Kim, Yu Ri, et al.
Publicado: (2022)

Cerebral Infarction in IgG Multiple Myeloma with Hyperviscosity
por: Park, Man-Seok, et al.
Publicado: (2005)

Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens
por: Hyun, Shin Young, et al.
Publicado: (2016)

DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation
por: Jang, Ji Eun, et al.
Publicado: (2023)

Tumor Necrosis Factor and Regulatory T Cells
por: Jung, Min Kyung, et al.
Publicado: (2019)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

P894: A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT
por: Byun, J. M., et al.
Publicado: (2022)

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
por: Park, Hyunsung, et al.
Publicado: (2017)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2017)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

Ribavirin Does Not Impair the Suppressive Activity of Foxp3(+)CD4(+)CD25(+) Regulatory T Cells
por: Lee, Jeewon, et al.
Publicado: (2013)

P975: INTERIM ANALYSIS OF PHASE II STUDY OF DARATUMUMAB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED 1 PRIOR LINE OF THERAPY (KMM1906)
por: Yoo, K. H., et al.
Publicado: (2022)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

P1368: OUTPATIENT AUTOTRANSPLANTS FOR PERSONS WITH MULTIPLE MYELOMA
por: Sánchez-Raga, J. M., et al.
Publicado: (2022)

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023)

P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
por: Fazio, Francesca, et al.
Publicado: (2023)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells
por: Jang, Ji Eun, et al.
Publicado: (2020)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
por: Steer, A., et al.
Publicado: (2022)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

P847: BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.
por: Traini, Valentina, et al.
Publicado: (2023)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains in multiple myeloma-induced kidney injury
por: Tillmann, F. P.
Publicado: (2015)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
por: Byun, Ja Min, et al.
Publicado: (2022)

Landscapes of SARS-CoV-2-reactive CD8(+) T cells: heterogeneity of host immune responses against SARS-CoV-2
por: Koh, June-Young, et al.
Publicado: (2021)

P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRDR)
por: Chai, K. L., et al.
Publicado: (2022)

ZW800-1 for Assessment of Blood-Brain Barrier Disruption in a Photothrombotic Stroke Model
por: Lee, Sungsu, et al.
Publicado: (2017)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gve8qrrrrl1qtk99mefmuqo9u1